Newsletter Signup | Join Community
According to Lancet publication: PI3K - PARP inhibitor combination promising in ovarian cancer - future study warranted
There is no longer a “one-size-fits-all” approach to ovarian cancer treatment update on precision cancer medicines.
Chemotherapy and maintenance therapy options for recurrent ovarian cancer.
Survival at 2 years was 72.4% versus 40.9% with chemotherapy alone
Stay Current With Ovarian Cancer Treatment Advances & Connect with Others
Maintenance Therapy with Votrient Provides Benefit in Advanced Ovarian Cancer
Zejula in Combination With Keytruda Appears Promising in Patients With Platinum Resistant/Refractory Ovarian Cancer.
Looking for Long Term Survivors: https://www.massgeneral…
Great NOCC overview on maintenance therapy for ovarian cancer. …
Speak up and share your story of hope!https://mavendoctors…